Caris Life Sciences Unveils New Class of Oncology Leaders
CARIS LIFE SCIENCES® (NASDAQ: CAI), a frontrunner in precision medicine and AI-driven technology, recently welcomed 15 newly appointed physician-scientists into its prestigious 2025/2026 Caris Precision Oncology Alliance (Caris POA) Fellows Forum. This competitive program aims to cultivate the next wave of oncology experts through rigorous training, mentorship, and invaluable access to molecular data.
Successful applicants are physician-scientists currently in their oncology fellowship at one of Caris' POA associated institutions. The selection process was highly competitive, emphasizing the candidates' academic credentials, research history, and passion for molecular oncology. Each fellow will gain:
Benefits of the Caris POA Fellows Program
1. Direct mentorship from seasoned Caris professionals and renowned faculty within Caris POA institutions.
2. Access to the extensive CODEai database, which compiles molecular data and treatment outcomes for over 484,000 patients, offering insights from more than a million data points per patient.
3. Opportunities for collaborative research across 97 cancer institutions and research entities.
4. A robust educational framework, comprising structured modules, virtual seminars, and lab observational visits.
As expressed by James Hamrick, MD, MPH, Chairman of the Caris POA, "By investing in emerging leaders in oncology, we can advance research and facilitate groundbreaking discoveries that transform cancer treatment and diagnosis. This year’s cohort symbolizes the future of precision oncology, and we are thrilled to support their development.”
These fellows will integrate the program into their monthly commitments, engaging in data analysis, mentorship sessions, and seminars designed to elevate their proficiency in molecular oncology. Collaboration among fellows is encouraged, with regular gatherings to share insights and foster community. Such events include guided tours of Caris' state-of-the-art Blood and Tissue Labs in Phoenix, the Caris POA Summit coinciding with the ASCO Annual Meeting, and monthly virtual workshops to discuss research updates and skills enhancement.
Emil Lou, MD, PhD, FACP, a key figure in the University of Minnesota's Division of Hematology, Oncology, and Transplantation, stated, "As Chair of the Caris Precision Oncology Alliance Fellows Forum, I proudly support our mission of nurturing the next generation of oncology leaders. By mentoring these fellows, we strive to use molecular insights to drive discoveries that will enhance patient care for years to come.”
Meet the 2025-2026 Fellows
The following accomplished individuals will represent the 2025-2026 Caris Precision Oncology Alliance Fellows Forum:
- Akram Alkrekshi, MD, MedStar Georgetown University Hospital
- Stefan Barisic, MD, Hematology & Medical Oncology Fellow, Duke University Hospital
- Paul Stendahl Dy, MD, MBA, University of Maryland Greenebaum Comprehensive Cancer Center
- Bharath Ganesh, MD, FACP, PGY-4 Hematology/Oncology Fellow, Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
- Kevin C. Graf, MD, Medical University of South Carolina
- Christopher Grant, MD, PGY-5, Division of Hematology-Oncology, UC San Diego School of Medicine
- Jennifer Hwang, MD, Hematology & Medical Oncology Fellow, The Ohio State University
- Anand Kornepati, MD, PhD, Hematology & Medical Oncology Fellow, Duke University Hospital
- Samantha Leite MD, Gynecologic Oncology Fellow, National Capital Consortium
- Dan Morgenstern Kaplan, MD, MSc, First Year Hematology/Oncology Fellow, Sylvester Comprehensive Cancer Center at the University of Miami
- Janina Pearce, MD, PhD, Women and Infants Hospital/Brown University
- Natalie Reed, DO, PGY-4, Hematology Oncology Fellow, Atrium Health Levine Cancer
- Ryan Michael Reyes, MD, PhD, Washington University School of Medicine in St. Louis
- Kelsey Roof, MD, Emory University School of Medicine
- Grace Sun, MD, Clinical Fellow in Hematology-Oncology, UC Davis Comprehensive Cancer Center
About Caris Life Sciences
Caris Life Sciences is at the forefront of patient-centric innovation, combining advanced AI technologies with precision medicine to revolutionize healthcare. With a focus on comprehensive molecular profiling through Whole Exome and Whole Transcriptome Sequencing, Caris leverages cutting-edge AI and machine learning to develop robust diagnostic tools that aid in early detection, accurate diagnosis, effective treatment selection, and groundbreaking drug development.
Founded with the aim to harness the potential of precision medicine, Caris has a significant presence in Irving, Texas, with additional offices located in key cities across the globe, ensuring the availability of its services not only domestically but also in numerous international markets.
Frequently Asked Questions
What is the Caris Precision Oncology Alliance?
The Caris Precision Oncology Alliance is a collaboration aimed at enhancing precision medicine through shared knowledge and resources among institutions.
How are fellows selected for the program?
Fellows are chosen based on academic achievements, research experience, and their potential in the field of molecular oncology.
What kind of training do fellows receive?
The program offers hands-on training, mentorship, and access to extensive molecular databases for practical research applications.
Where can the Caris fellows be based?
Fellows come from various esteemed institutions affiliated with the Caris Precision Oncology Alliance.
What impact does this program aim to have on oncology?
The program focuses on developing the next generation of oncology leaders to improve cancer diagnostic and treatment methods through innovative research.
